Charles Schwab’s Kailera Therapeutics KLRA Stock Holding History

Charles Schwab’s Portfolio KLRA Stock Details KLRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.99M	Buy	+362,910	New	+$7.98M	﹤0.01%	2264

Other funds holding KLRA

BCI

Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Charles Schwab's KLRA Position: Q2 2026 in Review

Charles Schwab opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 362,910 shares worth $7.99M. The stake represents ﹤0.01% of the portfolio and ranks #2264 among its holdings.

99 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

Charles Schwab held 362,910 shares of Kailera Therapeutics worth $7.99M as of Q2 2026.
Kailera Therapeutics was a new Charles Schwab position in Q2 2026.
Kailera Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2264 holding.
99 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.